Critical evaluation of permeation enhancers for oral mucosal drug delivery

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 254-282

  Sohi, Harmik ^a   Ahuja, Alka ^b   Ahmad, Farhan Jalees ^b   Khar, Roop Krishen ^b  

^a Panacea Biotec Ltd   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Buccal; Membrane damage; Oral mucosal delivery; Permeation enhancement; Toxicity

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; BENZALKONIUM CHLORIDE; BILE SALT; BUSERELIN; BUSPIRONE; CETRIMIDE; CETYLPYRIDINIUM SALT; CHELATING AGENT; CHOLIC ACID; CLOMIPRAMINE; CYCLODEXTRIN DERIVATIVE; DODECYL SULFATE SODIUM; ERGOTAMINE TARTRATE; FATTY ACID DERIVATIVE; GLYCERYL TRINITRATE; GLYCODEOXYCHOLIC ACID; ISOSORBIDE DINITRATE; MACROGOL STEARATE; OCTREOTIDE; PENETRATION ENHANCING AGENT; PHOSPHOLIPID; POLIDOCANOL; POLYMER; PROPRANOLOL; RECOMBINANT HUMAN INSULIN; SURFACTANT; TAUROCHOLIC ACID; TESTOSTERONE; UNINDEXED DRUG;

CELL JUNCTION; CELL MEMBRANE FLUIDITY; CHEEK MUCOSA; DENATURATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; ELECTROOSMOSIS; ELECTROPORATION; ENZYME INHIBITION; FUNCTIONAL ANATOMY; HUMAN; IONTOPHORESIS; LAMINA PROPRIA; MEMBRANE PERMEABILITY; MICELLIZATION; MOUTH MUCOSA; NONHUMAN; PERMEABILITY BARRIER; REVIEW;

EID: 77249093105     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903117348     Document Type: Review

References (238)

1. Harris D, Robinson JR. (1992). Drug delivery via the mucosa membrane of oral cavity. J Pharm Sci, 81:1-10.
2. Shojaei AH. (1998). Buccal mucosa as a route for systemic drug delivery. J Pharm Pharm Sci, 1:15-30.
3. Gandhi RB, Robinson JR. (1994). Oral cavity as a site for bioadhesive drug delivery. Adv Drug Deliv Rev, 13:43-74.
4. de Vries ME, Bodde HE, Verhoef JC, Junginger HE. (1991). Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst, 8:271-303.
5. Rathbone MJ, Hadgraft J. (1991). Absorption of drugs from the human oral cavity. Int J Pharm, 74:9-24.
6. Squier CA. (1991). The permeability of oral mucosa. Crit Rev Oral Biol Med, 2:13-32.
7. Rathbone MJ, Drummond BK, Tucker IG. (1994). The oral cavity as a site for systemic drug delivery. Adv Drug Deliv Rev, 13:1-22.
8. Bodde HE, de Vries ME, Junginger HE. (1990). Mucoadhesive polymers for the buccal delivery of peptides, structureadhesiveness relationships. J Control Release, 13:225-231
9. Wertz PW, Squier CA. (1991). Cellular and molecular basis of barrier function in oral epithelium. Crit Rev Ther Drug Carrier Syst, 8:237-269
10. Squier CA, Wertz PW. (1996). Structure and function of oral mucosa and implications for drug delivery. In: Rathbone MJ, ed. Oral mucosal drug delivery. New York: Marcel Dekker, Inc., 1-26.
11. Zhang H, Zhang J, Streisand JB. (2002). Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet, 41:661-680
12. Collins LMC, Dawes C. (1987). The surface area of adult human mouth and thickness of salivary film covering the teeth and oral mucosa. J Dent Res, 66:1300-1302
13. Lesch C, Squier CA, Cruchley AH, Williams DM, Speight PM. (1989). The permeability of human mucosa and skin to water. J Dent Res, 68:1345-1349
14. Kurosaki Y, Kimura T. (2000). Regional variation in oral mucosal drug permeability. Crit Rev Ther Drug Carrier Syst, 17:467-508.
15. Galey WR, Lonsdale HK, Nacht S. (1976). The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J Invest Dermatol, 67:713-717
16. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. (2001). Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm, 51:93-109.
17. Mashru RC, Sutariya VB, Sankalia MG, Sankalia JM. (2005). Effect of pH on in vitro permeation of ondansetron hydrochloride across porcine buccal mucosa. Pharm Dev Technol, 10:241-247.
18. Sutariya VB, Mashru RC, Sankalia MG, Sankalia JM. (2005). Transbuccal delivery of salbutamol sulphate: In vitro determination of routes of buccal transport. Ars Pharm, 46:337-352
19. Rathbone MJ, Tucker IG. (1993). Mechanism, barriers and pathways of oral mucosal drug permeation. Adv Drug Deliv Rev, 12:41-60.
20. Selvaratnam L, Cruchley AT, Navsaria H, Wertz PW, Hagi-Pavli EP, Leigh IM, et al. (2001). Permeability barrier properties of oral keratinocyte cultures: A model of intact human oral mucosa. Oral Dis, 7:252-258
21. Rathbone MJ, Ponchel G, Ghazali FA. (1996). Systemic oralmucosal drug delivery systems. In: Rathbone MJ, ed. Oral mucosal drug delivery. New York: Marcel Dekker, Inc., 241-284
22. Adams D. (1975). The mucin barrier and absorption through oral mucosa. J Dent Res, 54:1319-1326
23. Siegel IA. (1984). Permeability of oral mucosa. In: Meyer J, Squier CA, Gerson SJ. eds. The structure and function of oral mucosa. Oxford: Permagon Press, 95-108.
24. Robinson JR, Yang X. (1999). Absorption enhancers. In: Swarbrick J, Boylan JC, eds. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker, Inc., 1-27.
25. Smart JD. (1992). Some formulation factors influencing the rate of drug release from bioadhesive matrices. Drug Dev Ind Pharm, 18:223-232
26. Khanvilkar K, Donovan MD, Flanagan DR. (2001). Drug transfer through mucus. Adv Drug Deliv Rev, 48:173-193
27. Reid CO, Hardcastle J, Smith CJ. (1986). A comparison of some of the characteristics of intact and tape-stripped hamster cheek pouches in vitro. J Dent Res, 65:673-676
28. Garren KW, Repta AJ. (1989). Buccal drug absorption. II. In vitro diffusion across the hamster cheek pouch. J Pharm Sci, 2:160-164
29. Dowty ME, Knuth KE, Irons BK, Robinson JR. (1992). Transport of thyrotropin releasing hormone (TRH) in rabbit buccal mucosa in vitro. Pharm Res, 9:1113-1122
30. Gandhi RB, Robinson JR. (1992). Mechanism of penetration enhancement for transbuccal delivery of salicylic acid. Int J Pharm, 85:129-140
31. Squier CA, Rooney L. (1976). The permeability of keratinized and non-keratinized epithelium to lanthanum in vivo. J Ultrastruct Res, 54:286-295
32. Hill MW, Squier CA. (1979). The permeability of rat palatal mucosa maintained in organ culture. J Anat, 128:169-178
33. Squier CA, Hall BK. (1985). The permeability of skin and oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier. J Invest Dermatol, 84:176-179
34. Squier CA, Hall BK. (1986). The permeability of mammalian non-keratinized oral epithelia to horseradish peroxidase applied in vivo and in vitro. Arch Oral Biol, 29, 45-50.
35. Dowty ME, Knuth KE, Robinson JR. (1992). Enzyme characterization studies on the rate-limiting barrier in rabbit buccal mucosa. Int J Pharm, 88:293-302.
36. Kurosaki Y, Nishimura H, Terao K, Nakayama T, Kimura T. (1992). Existence of a specialized absorption mechanism for cefadroxil, an aminocephalosporin antibiotic, in the human oral cavity. Int J Pharm, 82:165-169
37. Siegel IA, Gordon HP. (1979). Penetration of oral mucosa by organic compounds. J Dent Res, 58:109.
38. Manning AS, Evered DF. (1976). The absorption of sugars from human oral cavity. Clin Sci Mol Med, 51:127-132
39. Darwish M, Tempero K, Kirby M, Thompson J. (2006). Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus Oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 ?g: A single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther, 28:715-724
40. Le Brun PPH, Fox PLA, de Vries ME, Bodde HE. (1989). In vitro penetration of some beta-adrenoreceptor blocking drugs through porcine buccal mucosa. Int J Pharm, 49:141-145
41. Siegel IA. (1984). Permeability of rat oral mucosa to organic solutes measured in vivo. Arch Oral Biol, 29:13-16.
42. Zhang J, Streisand J, Niu S, McJames S, Freimann V, Hague B, et al. (1992). Estimation of buccal absorption bioavailability by measuring drug depletion from vehicle solutions: Validation of methods in dogs. Pharm Res, 9:S-177.
43. Squier CA, Lesch CA. (1988). Penetration pathways of different compounds through epidermis and oral epithelia. J Oral Pathol, 17:512-516
44. Zhang J, Ebert CD, McJames S, Gijsman H, Stanley TH. (1989). Transmucosal permeability of isoproterenol in the dog model. Pharm Res, 6:S-135.
45. Hoogstraate AJ, Bodde HE, Cullander C, Junginger HE. (1992). Diffusion rates and transport pathways of FITC-labeled model compounds through buccal epithelium. Pharm Res, 9:S-188.
46. Kimura T, Yamano H, Tanaka A, Matsumura T, Ueda M, Ogawara K, et al. (2002). Transport of D-glucose across cultured stratified cell layer of human oral mucosal cells. J Pharm Pharmacol, 54:213-219
47. Sadoogh-Abasian F, Evered DF. (1979). Absorption of vitamin C from the human buccal cavity. Br J Nutr, 42:15-20.
48. Evered DF, Sadoogh-Abasian F, Patel PD. (1980). Absorption of nicotinic acid and nicotinamide across human buccal mucosa in vivo. Life Sci, 27:1649-1651
49. Utoguchi N, Watanabe Y, Suzuki T, Maehara J, Matsumoto Y, Matsumoto M. (1997). Carrier-mediated transport of monocarboxylic acids in primary cultured epithelial cells from rabbit oral mucosa. Pharm Res, 14:320-324
50. Utoguchi N, Watanabe Y, Takase Y, Suzuki T, Matsumoto M. (1999). Carrier-mediated absorption of salicylic acid from hamster cheek pouch mucosa. J Pharm Sci, 88:142-146
51. Kurosaki Y, Yano K, Kimura T. (1998). Perfusion cells for studying regional variation in oral mucosal permeability in humans. 2. A specialized transport mechanism in D-glucose absorption exists in dorsum of tongue. J Pharm Sci, 87:613-615
52. Brayton JJ, Yang Q, Nakkula RJ, Walters JD. (2002). An in vitro model of ciprofloxacin and minocycline transport by oral epithelial cells. J Periodontol, 73:1267-1272
53. Tavakoli-Saberi MR, Audus KL. (1989). Cultured buccal epithelium: An in vitro model derived from the hamster pouch for studying drug transport and metabolism. Pharm Res, 6:160-166
54. Nielsen HM, Rassing MR. (1999). TR146 cells grown on filters as a model of human buccal epithelium. III. Permeability enhancement by different pH values, different osmolality values, and bile salts. Int J Pharm, 185:215-225
55. Nielsen HM, Rassing, MR. (2000). TR 146 cells grown on filters as a model of human buccal epithelium. V. Enzyme activity of the TR 146 cell culture model, human buccal epithelium and porcine buccal epithelium and permeability of leuenkephalin. Int J Pharm, 200:261-270
56. Walle T, Walle UK, Sedmera D, Klausner M. (2006). Benzo[A]pyrene-induced oral carcinogenesis and chemoprevention: Studies in bioengineered human tissue. Drug Metab Dispos, 34:346-350
57. Kubilus J, Ayehunie S, Breyfogle B, Dale DA, Kimball J, Wertz P, Klausner M. (2006). Characterization and testing of new buccal and gingival tissue models. Amer Assoc Dent Res Meet, Abstract 399.
58. Agarwal V, Habib W, Moe D. (2005). Effervescent mediated transmucosal enhancement of fentanyl permeability: Comparison across ex vivo porcine buccal mucosa and in vitro cultured human buccal epithelium test. Amer Assoc Pharm Sci, Abstract T2126.
59. Portenoy RK, Taylor D, Messins J, Tremmel L. (2006). A randomized, placebo controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain, 22:805-811 (Pubitemid 44627444)
60. Zhang H, Robinson JR. (1996). Routes of drug transport across oral mucosa. In: Rathbone MJ, ed. Oral Mucosal Drug Delivery. New York: Marcel Dekker, Inc., 51-63.
61. Squier CA, Johnson NW. (1975). Permeability of oral mucosa. Br Med Bull, 3:169-175
62. Beckett AH, Triggs EJ. (1967). Buccal absorption of basic drugs and its application as an in-vivo model of passive drug transfer through lipid membranes. J Pharm Pharmacol, 19(Suppl.):31S-41S.
63. Beckett AH, Moffat AC. (1968). The influence of alkyl substitution in acids on their performance in the buccal absorption test. J Pharm Pharmacol, 20(Suppl.):239S-247S.
64. Beckett AH, Moffat AC. (1969). The influence of substitution in phenylacetic acids on their performance in the buccal absorption test. J Pharm Pharmacol, 21(Suppl.):139S-143S.
65. Beckett AH, Moffat AC. (1970). Kinetics of buccal absorption of some carboxylic acids and the correlation of the rate constant and n-heptane: Aqueous phase partition coefficients. J Pharm Pharmacol, 22:15-19.
66. Evered DF, Vadgama JV. (1981). Absorption of amino acids from the human buccal cavity. Biochem Soc Trans, 9:132-133
67. Evered DF, Mallett C. (1983). Thiamine absorption across human buccal mucosa in vivo. Life Sci, 32:1355-1358
68. McElnay JC, Temple DJ. (1982). The use of buccal partitioning as a model to examine the effects of aluminum hydroxide gel on the absorption of propranolol. Br J Clin Pharmacol, 13:399-403.
69. McElnay JC, Sidahmed AM, D'Arcy PF. (1982). Examination of the chloroquine-kaolin drug absorption interaction using the buccal partitioning model. J Clin Hosp Pharm, 7:269-273
70. Dearden JC, Tomlinson E. (1971). Correction for effect of dilution on diffusion through the membrane. J Pharm Sci, 60:1278-1279
71. Schurmann W, Turner P. (1978). A membrane model of the human oral mucosa as derived from buccal absorption performance and physicochemical properties of the beta-blocking drugs actenolol and propranolol. J Pharm Pharmacol, 30:137-147
72. Tucker IG. (1988). A method to study the kinetics of oral mucosal drug absorption from solutions. J Pharm Pharmacol, 40:679-683
73. Veillard MM, Longer MA, Martens TW, Robinson JR. (1987). Preliminary studies of oral mucosal delivery of peptide. J Control Release, 6:123-131
74. Barsuhn CL, Olanoff LS, Gleason DD, Adkins EL, Ho NF. (1988). Human buccal absorption of flurbiprofen. Clin Pharmacol Ther, 44:225-231
75. Yamahara H, Suzuki T, Mizobe M, Noda K, Samejima M. (1990). In situ perfusion system for oral mucosal absorption in dogs. J Pharm Sci, 79:963-967
76. Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JKH. (1992). The transport barrier of epithelia: A comparative study on membrane permeability and change selectivity in the rabbit. Pharm Res, 9:1029-1034
77. Senel S, Hincal AA. (2001). Drug permeation enhancement via buccal route: Possibilities and limitations. J Control Release, 72:133-144
78. Aungst A. (1994). Permeability and metabolism as barriers to transmucosal delivery of peptides. In: Hsein DS, ed. Drug permeation enhancement-Theory and applications. New York: Marcel Dekker, Inc., 323-343
79. Verhoef JC, Bodde HE, DeBoer AG, Bouwstra JA, Junginger HE, Merkus FW, et al. (1990). Transport of peptide and protein drugs across biological membranes. Eur J Drug Metab Pharmacokinet, 15:83-93.
80. Ganem-Quintanar A, Kalia YN, Falson-Rieg F, Buri P. (1997). Mechanisms of oral permeation enhancement. Int J Pharm, 156:127-142
81. Shojaei AH. (1998). Transbuccal delivery of acyclovir: In vitro determination of routes of buccal transport. Pharm Res, 15:1182-1188
82. Chen LL, Chetty DJ, Chien YW. (1999). A mechanistic analysis to characterize oramucosal permeation properties. Int J Pharm, 184:63-72.
83. Squier CA, Kremer MJ, Bruskin A, Rose A, Haley JD. (1999). Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro. Pharm Res, 16:1557-1563
84. Chetty DJ, Chen LL, Chien YW. (2001). Characterization of captopril sublingual permeation: Determination of preferred routes and mechanisms. J Pharm Sci, 90:1868-1877
85. Nicolazzo JA, Reed BL, Finnin BC. (2005). Buccal penetration enhancers-How do they really work? J Control Release, 105:1-15.
86. Junginger HE, Hoogstraate AJ, Verhoef JC. (1999). Recent advances in buccal delivery and absorption-In vitro and in vivo studies. J Control Release, 62:149-159
87. Lee VHL. (1999). Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J Control Release, 13:213-223
88. Nicolazzo JA, Reed BL, Finnin BC. (2004). Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol. J Pharm Sci, 93:431-440
89. Deneer VH, Drese GB, Roemele PE, Verhoef JC, Lie-A-Huen L, Kingma JH, et al. (2002). Buccal transport of flecainide and sotalol: Effect of a bile salt and ionization state. Int J Pharm, 241:127-134
90. Hoogstraate AJ, Senel S, Cullander C, Verhoef JC, Junginger HE, Bodde HE. (1996). Effects of bile salts on transport rates and routes of FITC-labeled compounds across porcine buccal epithelium in vitro. J Control Release, 40:211-221
91. Xiang J, Fang X, Li X. (2002). Transbuccal delivery of 2?,3?- dideoxycytidine: In vitro permeation study and histological investigation. Int J Pharm, 231:57-66.
92. Modi P, Mihic M, Lewin A. (2002). The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist system. Diabetes Metab Res Rev, 18(Suppl. 1):S38-42.
93. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. (2004). Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther, 26:2084-2091
94. Bernstein G. (2008). Delivery of insulin to the buccal mucosa utilizing the RapidMist™ system. Expert Opin Drug Del, 5(9):1047-1055
95. Ogiso T, Shintani M. (1990). Mechanism for the enhancement effect of fatty acids on the percutaneous absorption of propranolol. J Pharm Sci, 76:1065-1071
96. Aungst BJ, Rogers NJ. (1989). Comparisons of the effects of various transmucosal absorption promoters on buccal insulin delivery. Int J Pharm, 53:227-235
97. Kitigawa S, Yokochi N, Murooka N. (1995). pH dependence of phase transition of the lipid bilayer of liposomes of stratum corneum lipids. Int J Pharm, 126:49-56.
98. Morishita M, Barichello JM, Takayama K, Chiba Y, Tokiwa S, Nagai T. (2001). Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. Int J Pharm, 212:289-293
99. Manganaro AM, Wertz PW. (1996). The effects of permeabilizers on the in vitro penetration of propranolol through porcine buccal epithelium. Mil Med, 161:669-672
100. Birudaraj R, Berner B, Shen S, Li X. (2004). Buccal permeation of buspirone: Mechanistic studies on transport pathways. J Pharm Sci, 94:70-78
101. Tsutsumi K, Obata Y, Loftsson T, Takayama K, Nagai T. (1998). Effect of cod-liver oil extract (CLOE) on the buccal permeation of ergotamine tartarate. Drug Dev Ind Pharm, 24:757-762 (Pubitemid 28346450)
102. Tsutsumi K, Obata Y, Takayama K, Loftsson T, Nagai T. (1998). Effect of the cod-liver oil extract on the buccal permeation of ionized and non-ionized forms of ergotamine using the keratinized epithelial-free membrane of hamster cheek pouch mucosa. Int J Pharm, 174:151-156
103. Tsutsumi K, Obata Y, Nagai T, Loftsson T, Takayama K. (2002). Buccal absorption of ergotamine tartarate using the bioadhesive tablet system in guinea pigs. Int J Pharm, 238:161-170
104. Ceschel GC, Maffei P, Moretti DL, Demontis S, Peana AT. (2000). In vitro permeation through porcine buccal mucosa of Salvia desoleana Atzei and Picci essential oil from topical formulations. Int J Pharm, 195:171-177
105. Ganem-Quintanar A, Quintanar-Guerrero D, Falson-Rieg F, Buri P. (1998). Ex vivo oral mucosal permeation of lidocaine hydrochloride with sucrose fatty acid esters as absorption enhancers. Int J Pharm, 173:203-210 (Pubitemid 29027774)
106. Einarsson M. (1998). Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters. US patent 5714477.
107. Lee J, Kellaway IW. (2000). Buccal permeation of [D-Ala2, D-Leu5]enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm, 195:35-38
108. Lee J, Kellaway IW. (2000). Combined effect of oleic acid and polyethylene glycol 200 on buccal permeation of [D-Ala2, D-Leu5]enkephalin from a cubic phase of glyceryl monooleate. Int J Pharm, 204:137-144
109. Burgalassi S, Chetoni P, Dini L, Najarro M, Monti D, Morelli P, et al. (2006). Effect of permeation enhancers on buccal absorption. Arzneimittelforschung, 56:561-567
110. Hague B, Stanley T. (1998). Compositions and methods of manufacturing of oral dissolvable medicaments. US patent 5785989.
111. Hague B, Stanley T. (1999). Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient. US patent 5855908.
112. Ikinci G, Senel S, Akincibay H, Kas S, Erics S, Hincal AA, et al. (2002). Effect of chitosan on a periodontal pathogen porphyromonas gingivalis. Int J Pharm, 235:121-127
113. Senel S, Kremer MJ, Kas SH, Wertz PW, Hincal AA, Squier CA. (2000). Effect of chitosan in enhancing drug delivery across buccal mucosa. In: Pertz MG, Muzzarelli RAA, Domard A, eds. Advances in chitin science. Potsdam: University of Potsdam, 254-258
114. Needleman IG, Smales FC, Martin GP. (1997). An investigation of bioadhesion for periodontal and oral mucosal drug delivery. J Clin Periodontol, 24:394-400.
115. Illum L, Farraj NF, Davis SS. (1994). Chitosan as a novel delivery system for peptide drugs. Pharm Res, 11:1186-1189
116. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on permeability of monolayers of intestinal epithelial cells (CaCo-2). Pharm Res, 11:1358-1361
117. Schipper NG, Olsson S, Hoogstraate JA, DeBoer AG, Varum KM, Artursson P. (1997). Chitosan as absorption enhancers for poorly absorbable drugs. 2: Mechanism of absorption enhancement. Pharm Res, 14:923-929
118. Kremer MJ, Senel S, Kas SH, Wertz PW, Hincal AA, Squier, CA. (1999). Oral mucosal drug delivery: Chitosan as a vehicle and permeablizer. J Dent Res, 77: 718.
119. Senel S, Kremer MJ, Kas SH, Wertz PW, Hincal AA, Squier CA. (2000). Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials, 21:2067-2071
120. Portero A, Remunan-Lopez C, Nielsen HM. (2002). The potential of chitosan in enhancing peptide and protein absorption across TR146 cell culture model-an in vitro model of the buccal epithelium. Pharm Res, 19:169-174
121. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Muzzarelli C, Caramela C. (2004). Assessment of chitosan derivatives as buccal and vaginal permeation enhancers. Eur J Pharm Sci, 21:351-359
122. Sandri G, Rossi S, Bonferoni MC, Ferrari F, Zambito Y, DiColo G, et al. (2005). Buccal penetration enhancement properties of N-trimethyl chitosan: Influence of quaternization degree on absorption of a high molecular weight molecule. Int J Pharm, 297:146-155 (Pubitemid 40720274)
123. Sandri G, Poggi P, Bonferoni MC, Rossi S, Ferrari F, Caramella C. (2006). Histological evaluation of buccal penetration enhancement properties of chitosan and trimethyl chitosan. J Pharm Pharmacol, 58:1327-1336
124. Van der Merwe SM, Verhoef JC, Verheijden JH, Kotze AF, Junginger HE. (2004). Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm, 58:225-235
125. Langoth N, Kalbe J, Bernkop-Scnhurch A. (2005). Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide). Int J Pharm, 296:103-111 (Pubitemid 40693378)
126. Langoth N, Bernkop-Scnhurch A, Kurka P. (2005). In vitro evaluation of various buccal permeation enhancing systems for PACAP (pituitary adenylate cyclase-activating polypeptide). Pharm Res, 22:2045-2050 (Pubitemid 41821583)
127. Langoth N, Kahlbacher H, Schoffmann G, Schmerold I, Schuh M, Franz S, et al. (2006). Thiolated chitosans: Design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system. Pharm Res, 23:573-579
128. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Zerrouk N, Caramella C. (2004). Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol, 56:1083-1090
129. Brewster ME, Hora MS, Simpkins JW, Bodor N. (1991). Use of 2-hydroxypropyl-?-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res, 8:792-795
130. Pitha J, Harman SM, Michel ME. (1986). Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J Pharm Sci, 75:165-167
131. Pitha J, Anaissie EJ, Uekama K. (1987). Gamma-cyclodextrin: Testosterone complex suitable for sublingual administration. J Pharm Sci, 76:788-790
132. Yoo SD, Yoon BM, Lee HS, Lee KC. (1999). Increased bioavailability of clomipramine after sublingual administration in rats. J Pharm Sci, 88:1119-1121
133. Jacobsen J, Bjerregaard S, Pederson M. (1999). Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR 146 cells and release from a delivery system. Eur J Pharm Biopharm, 48:217-224
134. Jain AC, Aungst BJ, Adeyeye MC. (2002). Development and in vitro evaluation of buccal tablets prepared using danazolsulfobutylether- 7-?-cyclodextrin (SBE7) complexes. J Pharm Sci, 91:1659-1668
135. Cappello B, Rosa GD, Giannini L, Rotonda MIL, Mensitieri G, Miro A, et al. (2006). Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: Potential as buccal delivery system. Int J Pharm, 319:63-70.
136. Nantwi PK, Cook DJ, Rogers DJ, Smart JD. (1997). Lecithins for drug delivery within the oral cavity-investigation of lecithin binding to oral mucosa. J Drug Target, 5:45-55.
137. Coleman DL. (2002). Compositions and methods of manufacture for oral dissolvable dosage forms. US patent 2002160043.
138. Howie NM, Trigkas TK, Cruchley AT, Wertz PW, Squier CA, Williams DM. (2001). Short-term exposure to alcohol increases the permeability of human oral mucosa. Oral Dis, 7:349-354
139. Nicolazzo JA, Reed BL, Finnin BC. (2004). Modification of buccal drug delivery following pretreatment with skin penetration enhancers. J Pharm Sci, 93:2054-2063
140. Kitano M, Maitani Y, Takayama K, Nagai T. (1998). Buccal absorption through golden hamster cheek pouch in vitro and in vivo of 17?-estradiol from hydrogels containing three types of absorption enhancers. Int J Pharm, 174:19-28.
141. Ceschel GC, Maffei P, Sforzini A, Borgia SL, Yasin A, Ronchi, C. (2002). In vitro permeation through porcine buccal mucosa of caffeic acid phenetyl ester (CAPE) from a topical mucoadhesive gel containing propolis. Fitoterapia, 73:S44-52.
142. Kurosaki Y, Nakayama T, Kimura T. (1989). Enhancing effect of 1-dodecyclazacycloheptan-2-one (Azone) on the absorption of salicylic acid from keratinized oral mucosa and duration of enhancement in vivo. Int J Pharm, 51:47-54.
143. Nicolazzo JA, Reed BL, Finnin BC. (2005). Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J Control Release, 105:240-248
144. Xu H-B, Huang K-X, Zhu Y-S, Gao Q-H, Wu Q-Z, Tian W-Q, et al. (2002). Hypoglycaemic effect of a novel insulin buccal formulation on rabbits. Pharmacol Res, 46: 459-467
145. Yang TZ, Wang XT, Yan XY, Zhang Q. (2002). Phospholipid deformable vesicles for buccal delivery of insulin. Chem Pharm Bull (Tokyo), 50:749-753
146. Cui CY, Lu WL, Xiao L, Zhang SQ, Huang XB, Li SL, et al. (2005). Sublingual delivery of insulin: Effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity. Biol Pharm Bull, 28: 2279-2288
147. Zhu DD, Chen HB, Zheng JN, Du DR, Mou DS, Yang XL. (2006). Preparation and permeation studies of soybean lecithin-based vesicles. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 28:492-496
148. Starokadomskyy PL, Dubey IY. (2006). New absorption promoter for the buccal delivery: Preparation and characterization of lysalbinic acid. Int J Pharm, 308:149-154
149. Eichman JD, Robinson JR. (1998). Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res, 15:925-930
150. Pather SI, Khankari RK, Eichman JD, Robinson JR, Hontz J. (2005). Sublingual buccal effervescent. US patent 6974590.
151. Durfee S, Messina J, Khankari R. (2006). Fentanyl effervescent buccal tablets: Enhanced buccal absorption. Am J Drug Deliv, 4:1-5.
152. Darwish M, Tempero K, Kirby M, Thompson J. (2005). Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet, 44:1279-1286
153. Alur HH, Johnson TP, Mitra AK. (2001). Peptides and proteins buccal absorption. In: Swarbrick J, Boylan JC, eds. Encyclopedia of pharmaceutical technology (Suppl. 3). New York: Marcel Dekker, Inc., 193-218.
154. Vondracek M, Xi Z, Larson P, Baker V, Mace K, Pfeifer A, et al. (2001). Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis, 22:481-488
155. Robinson DA, Bogdanoffy MS, Reed CJ. (2002). Histochemical localization of carboxylesterase activity in rat and mouse oral cavity mucosa. Toxicology, 180:209-220
156. Yamamoto A, Hayakawa E, Lee VHL. (1990). Insulin and proinsulin in the mucosal homogenates of the albino rabbit: Implications in peptide delivery from normal routes. Life Sci, 47:2465-2474
157. Tavakoli-Saberi MR, Williams A, Audus KL. (1991). Aminopeptidase activity in human buccal epithelium and primary cultures of hamster buccal epithelium. Pharm Res, 6:S197.
158. Nakada Y, Awata N, Nakamichi C, Sugimoto I. (1987). Stability of human calcitonin in the supernatant of the rat's oral mucosa homogenate. Yakuzaigaku, 47:217-223
159. Hussain MA, Aungst BJ, Koval CA, Shefter E. (1988). Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm Res, 5:615-618
160. Hansen LB, Christrup LL, Bundgaard H. (1992). Enhanced delivery of ketobemidone through porcine buccal mucosa in vitro via more lipophilic ester prodrugs. Int J Pharm, 88:237-242
161. Bundgaard H, Moss J. (1990). Prodrug of peptides. 6. Bioreversible derivatives of thyrotropin releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by TRH-specific serum enzymes. Pharm Res, 7:885-892
162. Bundgaard H, Rasmussen GJ. (1991). Prodrugs of peptides. 9. Bioreversible N-?-hydroxyalkylation of the peptide bond to effect protection against carboxypeptidase or other proteolytic enzymes. Pharm Res, 8:313-322
163. Christrup LL, Christensen CB, Friis GJ, Jorgensen A. (1997). Improvement of buccal delivery of morphine using the prodrug approach. Int J Pharm, 154:157-165
164. Veuillez F, Ganem-Quintanar A, Deshusses J, Falson-Rieg F, Buri P. (1998). Comparison of the ex vivo oral mucosal permeation of tryptophan-leucine (Trp-Leu) and its myristoyl derivative. Int J Pharm, 170:85-91.
165. Walker GF, Langoth N, Bernkop-Schnurch A. (2002). Peptidase activity on the surface of porcine buccal mucosa. Int J Pharm, 233:141-147
166. Bird AP, Faltinek JR, Shojaei AH. (2001). Transbuccal peptide delivery: Stability and in vitro permeation studies on endomorphin-1. J Control Release, 73:31-36
167. Maffei P, Lombardi BS, Sorzine A, Bergamante V, Ceschel GS, Fini A, et al. (2004). Mucoadhesive tablets for buccal administration containing sodium nimesulide. J Microencap, 11:225-230
168. Scholz OA, Wolff A, Schumacher A, Giannola LI, Campisi G, Ciach T, et al. (2008). Drug delivery from the oral cavity: Focus on a novel mechatronic delivery device. Drug Discov Today, 13:247-253
169. LeDuc S. (1900). Introduction of medicinal substances into the depth of tissues by electric current. Ann D'Electrobiol, 3:545-560
170. Jacobsen J. (2001). Buccal iontophoretic delivery of atenolol HCl employing a new in vitro three-chamber permeation cell. J Control Release, 70:83-95.
171. Giannola LI, De Caro V, Giandalia G, Siragusa MG, Campisi G, Florena AM, et al. (2007). Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur J Pharm Biopharm, 65:238-246
172. Giannola LI, De Caro V, Giandalia G, Siragusa MG, Tripodo C, Florena AM, et al. (2007). Release of naltrexone on buccal mucosa: Permeation studies, histological aspects and matrix system design. Eur J Pharm Biopharm, 67:425-433
173. Moscicka AE, Czarnecka K, Ciach T. (2007). IntelliDrug implant for medicine delivery in Alzheimer's disease treatment. Macromol Symp, 253:134-138
174. Fish R. (1993). Electric shock. Part II. Nature and mechanism of injury. J Emerg Med, 11:457-462 (Pubitemid 23249634)
175. Moscicka-Studzinska A, Kijenska E, Ciach T. (2009). Electroosmotic flow as a result of buccal iontophoresis-Buccal mucosa properties. Eur J Pharm Biopharm, 72:595-599
176. Lavon I, Grossman N, Kost J, Kimmel E, Enden G. (2007). Bubble growth within the skin by rectified diffusion might play a significant role in sonophoresis. J Control Release, 117:246-255
177. Aungst BJ. (1996). Oral mucosal permeation enhancement: Possibilities and limitations. In: Rathbone MJ, ed. Oral mucosal drug delivery. New York: Marcel Dekker, Inc., 65-83.
178. Wertz PW, Swartzendruber DC, Squier CA. (1993). Regional variation in the structure and permeability of oral mucosa and skin. Adv Drug Deliv Rev, 12:1-12.
179. Kamath KR, Park K. (1994). Mucosal adhesive preparations. In: Swarbrick J, Boylan JC, eds. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker, Inc., 133-163
180. Turunen TM, Urtti A, Pargnen P, Audus KL, Rytting JH. (1994). Effect of some penetration enhancers on epithelial membrane lipid domains: Evidence from fluorescence spectroscopy studies. Pharm Res, 11:288-294
181. Swartzendruber DC, Manganaro A, Madison KC, Kremer M, Wertz PW, Squier CA. (1995). Organization of the intercellular spaces of epidermal and palatal stratum corneum: A quantitative study employing ruthenium tetroxide. Cell Tissue Res, 279:271-276
182. Ganem-Quintanar A, Falson-Rieg F, Buri P. (1996). Permeation enhancement
183. Gullikson GW, Cline WS, Lorenzsonn V, Benz L, Olsen WA, Bass P. (1977). Effects of anionic surfactants on hamster small intestinal membrane structure and function: Relationship to surface activity. Gastroenterology, 73:501-511
184. Ponec M, Haverkort M, Soei YL, Kempenarr J, Brussee J, Bodde HE. (1989). Toxicity screening of N-alkylazacycloheptan-2-one derivatives in cultured human cells: Structure-toxicity relationships. J Pharm Sci, 78:738-741
185. Chandler SG, Illum L, Thomas NW. (1991). Nasal absorption in rats. II. Effect of enhancers on insulin absorption and nasal histology. Int J Pharm, 76:61-70.
186. Boulmedarat L, Bochot A, Lesieur S, Fattal E. (2005). Evaluation of buccal methyl-beta-cyclodextrin toxicity on human oral epithelial cell culture model. J Pharm Sci, 94,1300-1309
187. Hoogstraate AJ, Verhoef JC, Tu KB, Pijpers A, Bodde HE, VanLeengoed LA, et al. (1996). In vivo buccal delivery of fluorescein isothiocynate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs. J Pharm Sci, 85:457-460 (Pubitemid 26150976)
188. Nakane S, Kakamuto M, Yukimatsu K, Chien YW. (1996). Oral mucosal delivery of LHRH: Pharmacokinetic studies of controlled and enhanced transmucosal permeation. Pharm Dev Technol, 1:251-259
189. Senel S, Capan Y, Sargon MF, Giray CB, Hincal AA. (1998). Histological and bioadhesion studies on buccal bioadhesive tablets containing a permeation enhancer sodium glycocholate. Int J Pharm, 170:239-245
190. Zhang J, Niu S, Ebert C, Stanley TH. (1994). An in vivo dog model for studying recovery kinetics of buccal mucosa permeation barrier after exposure to permeation enhancers: Apparent evidence of effective evidence enhancement without tissue damage. Int J Pharm, 101:15-22.
191. Siegel IA, Gordon HP. (1985). Effects of surfactants on the permeability of canine oral mucosa in vitro. Toxicol Lett, 26:153-157
192. Imbert D, Cullander C. (1999). Buccal mucosa in vitro experiments. I. Confocal imaging of vital staining and MTT assays for the determination of tissue viability. J Control Release, 58:39-50.
193. Imbert D, Cullander C. (1998). Assessing penetration enhancers for buccal delivery: Tools for simultaneous efficacy and toxicity screening using viable tissue samples [abstract]. Proc Int Symp Control Rel Bioact Mater, 25:26-27
194. Birudaraj R, Mahalingam R, Li X, Jasti BR. (2005). Advances in buccal drug delivery. Crit Rev Ther Drug Carrier Syst, 22:295-330.
195. Li B, Robinson JR. (2005). Preclinical assessment of oral mucosal drug delivery systems. In: Ghosh TK, Pfister WR, eds. Drug delivery to the oral cavity: Molecules to market. Boca Raton, FL: CRC Press, 41-66.
196. Squier CA, Nanny D. (1985). Measurement of blood flow in the oral mucosa and skin of the rhesus monkey using radiolabelled microspheres. Arch Oral Biol, 30:313-318
197. Worakul N, Robinson JR. (2001). Drug delivery via mucosal routes. In: Dimitriu S, ed. Polymeric biomaterials. New York: Marcel Dekker, Inc., 1031-1062
198. Obradovic T, Hidalgo IJ. (2007). In vitro models for investigations of buccal drug permeation and metabolism. In: Ehrhardt C, Kim K-J, eds. Drug absorption studies in situ, in vitro and in silico models, vol.VII. Arlington, VA: AAPS Press/Springer US, 167-181
199. Chauncey HH, Henriques BL, Tanzer JM. (1963). Comparative enzyme activity of saliva from the sheep, hog, dog, rabbit, rat and human. Arch Oral Biol, 8:615-627
200. Mundschenk DD. (2001). Buccal delivery system for proteinaceous medicaments. EP 1146890.
201. Modi P. (2002). Pharmaceutical compositions for buccal and pulmonary application. US patent 6375975.
202. Modi P. (2003). Method for administering insulin to the buccal region. US patent 2003171259.
203. Libbey MA, McCoy R, Williams RO. (2003). Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same. US patent 2003059376.
204. Andersson SB, Landh T, Jonn S, Gruden S, Lindberg N. (2004). Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption. US patent 6676959.
205. Modi P. (2004). Methods of administering and enhancing absorption of pharmaceutical agents. WO 2004016243.
206. Moonga G. (2004). Buccal tablet. GB 2394415.
207. Modi P. (2005). Pharmaceutical compositions for buccal delivery of pain relief medications. US patent 6849263.
208. Mathias NR, Li L. (2005). Composition for enhancing absorption of a drug and method. WO 2005115339.
209. Ahmed SU, Li LL, Naini V. (2006). Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same. US patent 2006002989.
210. Martyn GP, Coghlan DJ. (2006). Composition for delivery of an active agent. WO 2006010939.
211. Mundschenk DD. (2007). Buccal delivery System. US patent 2007014735.
212. Holl R, Osborne DW. (2007). Adhesive bioerodible transmucosal drug delivery system. US patent 20070207192.
213. Durfee SL, Thurman GB. (2008). Composition for transmucosal delivery of polypeptides. WO 2008137054.
214. Cunningham P. (2009). Caffeine delivery systems. US patent 2009047328.
215. Senel S, Duchene DD, Hincal AA, Capan Y, Ponchel G. (1998). In vitro studies on enhancing effect of sodium glycocholate on transbuccal permeation of morphine hydrochloride. J Control Release, 51:107-113
216. Johnston TP, Rahman A, Alur H, Shah D, Mitra AK. (1998). Permeation of unfolded basic fibroblast growth factor (bFGF) across rabbit buccal mucosa-does unfolding of bFGF enhances transport? Pharm Res, 15:246-253
217. Shojaei AH, Khan M, Lim G, Khosravan R. (1999). Transbuccal absorption of a nucleoside analog, dideoxycytidine: Effects of menthol as permeation enhancer. Int J Pharm, 192:139-146
218. Van der Bijl P, Penkler L, Van Eyk AD. (2000). Permeation of sumatriptan through human vaginal and buccal mucosa. Headache, 40:137-141
219. Jasti BR, Zhoue S, Mehta RC, Li X. (2000). Permeability of antisense oligonucleotide through porcine buccal mucosa. Int J Pharm, 208:35-39
220. Chin SC, Kim JY. (2000). Enhanced permeation of triamcinolone acetonide through the buccal mucosa. Eur J Pharm Biopharm, 50:217-220
221. Du X, Squier CA, Kremer MJ, Wertz PW. (2000). Penetration of N-nitrosonornicotine (NNN) across oral mucosa in the presence of ethanol and nicotine. J Oral Pathol Med, 29:80-85
222. Ikinci G, Capan Y, Senel S, Alaaddinglu E, Dalkara T, Hincal AA. (2000). In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine. Pharmazie, 55:762-765
223. Chun MK, Kwak BK, Choi HK. (2003). Preparation of buccal patch composed of carbopol, polaxamer and hydroxypropyl methyl cellulose. Arch Pharm Res, 26:973-978
224. Lee J, Choi YW. (2003). Enhanced ex vivo buccal transport of propranolol: Evaluation of phospholipids as permeation enhancers. Arch Pharm Res, 26:421-425
225. Artusi M, Santi P, Colombo P, Junginger HE. (2003). Buccal delivery of thiocolchicoside: In vitro and in vivo permeation studies. Int J Pharm, 250:203-213
226. El-Samaligy MS, Yahia SA, Basalious EB. (2004). Formulation and evaluation of diclofenac sodium buccoadhesive discs. Int J Pharm, 286:27-39.
227. Goswami T, Kokate A, Jasti B, Li X. (2006). Effect of permeation enhancers on the permeation of ionized and unionized nimesulide in buccal permeation. AAPS Ann Meet Expo, Abstarct M1234.
228. Shidhaye SS, Saindane NS, Sutar S, Kadam V. (2008). Mucoadhesive bilayered patches for administration of sumatriptan succinate. AAPS PharmSciTech, 9(3):909.
229. Wang Y, Zuo Z, Chow MSS. (2009). HO-1-u-1 model for screening sublingual drug delivery-influence of pH, osmolarity and permeation enhancer. Int J Pharm, 370:68-74.
230. Miro A, Rondinone A, Nappi A, Ungaro F, Quaglia F, Rotonda MIL. (2009). Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: Role of cyclodextrins and implications in oral drug delivery. Eur J Pharm Biopharm, 72:76-82.
231. Figueiras A, Hombach J, Veiga F, Bernkop-Schnürch A. (2009). In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm, 71:339-345
232. Ong CMY, Heard CM. (2009). Permeation of quinine across sublingual mucosa in vitro. Int J Pharm, 366:58-64.
233. Dhiman MK, Dhiman A, Sawant KK. (2009). Transbuccal delivery of 5-fluorouracil: Permeation enhancement and pharmacokinetic study. AAPS PharmSciTech, 10:258-265
234. Qiu Y, Johnson HW, Reiland TL, Lu M-YF. (1999). Sublingual absorption of leuprolide: Comparison between human and animal models. Int J Pharm, 179:27-36.
235. Chin SC, Bum JP, Choi JS. (2000). Enhanced bioavailability of buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. Int J Pharm, 209:37-43.
236. Martin L, Wilson CG, Koosha F, Uchegbu IF. (2003). Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels. Eur J Pharm Biopharm, 55:35-45.
237. Honsy EA, Elkheshen SA, Saleh SI. (2004). Buccoadhesive tablets for insulin delivery: In vitro and in vivo studies. Boll Chim Pharm, 141:210-217
238. Attia MA, El-Gibaly I, Shaltout SE, Fetih GN. (2004). Transmucosal permeation, anti-inflammatory and clinical efficacy of piroxicam formulated in different gels. Int J Pharm, 276:11-28.